期刊文献+

多巴胺重摄取的分子机制 被引量:9

Towards an understanding of molecular mechanisms underlying dopamine reuptake
原文传递
导出
摘要 多巴胺转运体(Dopamine transporter,DAT)位于多巴胺能神经元表面,主要负责将细胞外的多巴胺重摄取至多巴胺能神经元内,控制细胞外多巴胺的浓度,进而影响多巴胺的信号强度和时长。多巴胺转运体与注意力缺陷多动症、抑郁、成瘾等中枢神经系统的功能异常相关。多巴胺转运体的重摄取功能受多种因素的调节,包括底物的浓度、自身位点的翻译后修饰、细胞内蛋白激酶的活性、细胞外的调节信号等。本文就近年来DAT的分子调节机制以及在脑疾病发病机制中作用的研究进展做一综述。 Dopamine transporter (DAT) is normally localized in the cell surface of dopaminergic neurons and is responsible for regulating the concentration of dopamine in extracellular space by reuptaking dopamine into dopaminergic neurons. Dopaminergic neurotransmission is thus fine-turned. This mechanism has significant impact on the strength and duration of extracellular dopamine signals. Dysfunction of DAT has been associated with several brain disorders, such as attention-deficit hyperactivity disorder, depression, drug addiction. Recent reports have demonstrated that several factors, including the concentration of substrate, DAT post-translational modification, protein kinase activities and extracellular signals, contribute to the regulation of DAT function. In this review, we will discuss some of the recent research progress on the molecular mechanisms underlying dopamine reuptake and link changes in DAT trafficking to brain disorders.
出处 《生命的化学》 CAS CSCD 2014年第2期136-146,共11页 Chemistry of Life
基金 国家重点基础研究发展计划("973"计划)(2011CB504102) 国家自然科学基金项目(31123002 31321091和30621130075) 上海市科委项目(128014382)
关键词 多巴胺转运体 多巴胺 重摄取 转运 dopamine transporter dopamine reuptake endocytic trafficking
  • 相关文献

参考文献70

  • 1Laasonen-Balk T, Kuikka J, Viinamaki H, et al. Striatal dopamine transporter density in major depression.Psychopharmacology (Berl), 1999, 144(3): 282-285.
  • 2Dougherty, DD, Bonab AA, Spencer T J, et al. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet, 1999, 354(9196): 2132- 2133.
  • 3Larisch R, Sitte W, Antke C, et al. Striatal dopamine transporter density in drug naive patients with attention- deficit/hyperactivity disorder. Nucl Med Commun, 2006, 27(3): 267-270.
  • 4Anand A, Barkay G, Dzemidzic M, et al. Striatal dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disord, 2011, 13(4): 406-413.
  • 5Kristensen AS, Andersen J, Jorgensen TN, et al. SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev, 2011, 63 (3): 585-640.
  • 6Gether U, Andersen PH, Larsson OM, et al. Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol Sci, 2006, 27(7): 375-383.
  • 7Pramod AB, Foster J, Carvelli L, et al. SLC6 transporters: structure, function, regulation, disease association and therapeutics. Mol Aspects Med, 2013, 34(2-3): 197-219.
  • 8Moron JA, Brockington A, Wise RA, et al. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci, 2002, 22(2): 389-395.
  • 9Shimada S, Kitayama S, Lin CL, et al. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science, 1991, 254(5031): 576- 578.
  • 10Kilty JE, Lorang D, Amara SG. Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science, 1991, 254(5031): 578-579.

同被引文献125

引证文献9

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部